Neocate Syneo (amino acid formula supplemented with prebiotics, probiotics and long chain polyunsaturated fatty acids)
amino acid formula supplemented with prebiotics, probiotics and long chain polyunsaturated fatty acids powder for oral liquid, 400 g · ORAL · PBS code 11343B
AUTHORITY_REQUIREDWhat it costs
AU$34.63 PBS-determined price per 12 units
Most patients pay only the standard PBS co-payment, not the full price above — up to AU$25.00 per script (general) or AU$7.70 (concession/Safety Net) in 2026. The figure above is what the PBS pays the pharmacy; the Australian Government subsidises the rest. Always confirm the current amount with your pharmacist.
- • First listed on the PBS: 2018-05-01.
- • Repeats: 5.
- • PBS program: GE.
Eligibility criteria for subsidised access
The following is the government's own wording from the PBS Schedule, shown unchanged.
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
Eosinophilic oesophagitis
Initial treatment for up to 3 months
Must be treated by a clinical immunologist, suitably qualified allergist or gastroenterologist; AND
Patient must require an amino acid based formula as a component of a dietary elimination program; AND
Patient must be 18 years of age or less.
Treatment with oral steroids should not be commenced during the period of initial treatment.
Eosinophilic oesophagitis is demonstrated by the following criteria:
(i) Chronic symptoms of reflux that persisted despite a 2-month trial of a proton pump inhibitor or chronic dysphagia; and
(ii) A lack of demonstrable anatomic abnormality with the exception of stricture, which can be attributable to eosinophilic oesophagitis; and
(iii) Eosinophilic infiltration of the oesophagus, demonstrated by oesophageal biopsy specimens obtained by endoscopy and where the most densely involved oesophageal biopsy had 20 or more eosinophils in any single 400 x high powered field, along with normal antral and duodenal biopsies.
The date of birth of the patient must be included in the authority application.
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
Eosinophilic oesophagitis
Continuing treatment
Must be treated by a clinical immunologist, suitably qualified allergist or gastroenterologist; AND
Patient must have responded to an initial course of PBS-subsidised treatment; AND
Patient must be 18 years of age or less.
Response to initial treatment is demonstrated by oesophageal biopsy specimens obtained by endoscopy, where the most densely involved oesophageal biopsy had 5 or less eosinophils in any single 400 x high powered field, along with normal antral and duodenal biopsies. The response criteria will not be deemed to have been met if oral steroids were commenced during initial treatment.
Sponsor: Nutricia Australia Pty Limited ABN 99 076 246 752
Not medical advice. Voxsanity republishes public PBS data in plain English. PBS listing status and criteria can change; always confirm current subsidised availability with your doctor or pharmacist.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.